Radiothérapie ablative pour consolider la réponse systémique maximale dans le cancer de la prostate métastatique (ANCHOR-Prostate)

This study is looking for men who have prostate cancer that has spread to other parts of the body. Your cancer must be responding well to the hormone treatment you are receiving, meaning your PSA levels aren't rising. You also need to be fit enough for daily activities and the focused radiation should be a suitable option for where your cancer has spread.

Before you can be considered for this specific ANCHOR-Prostate study, you would first need to be part of another ongoing registry study called PERa. Your doctor would then assess if the focused radiation treatment is appropriate for your specific situation. This study is not for you if you are planning to have breaks in your hormone treatment or if you are scheduled for a specific type of radiation treatment called radio-ligand therapy.

Overall, the study is for adult men who have hormone-sensitive metastatic prostate cancer where the primary tumour has already been treated, or will be treated soon, and there’s no local recurrence.

If you join this study, you'll continue with your usual hormone therapy. Half of the participants will also be offered focused radiation (MDRT) to the areas where their cancer has spread, as seen on scans. If your PSA level remains above 0.2 ng/mL after the first course of MDRT, you might have another scan and a second course of radiation.

You'll have regular follow-up appointments to check your PSA levels and monitor the cancer. This usually involves blood tests and sometimes scans. The study will track your health and treatment outcomes over time, but the specific duration will depend on your individual treatment plan and progress. Neither you nor your doctor will know whether you'll be offered the extra radiation until you are randomly selected.